表紙:マイクロバイオーム治療の世界市場 - 産業規模、シェア、動向、機会、予測:タイプ別、用途別、地域別(2017年~2027年)
市場調査レポート
商品コード
1152250

マイクロバイオーム治療の世界市場 - 産業規模、シェア、動向、機会、予測:タイプ別、用途別、地域別(2017年~2027年)

Global Microbiome Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented By Type, By Application, By Region

出版日: | 発行: TechSci Research | ページ情報: 英文 114 Pages | 納期: 2~3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=152.41円

こちらのレポートには、数時間(ご購入金額の10%)分のアナリストへの質問/追加調査サービスが含まれております。

マイクロバイオーム治療の世界市場 - 産業規模、シェア、動向、機会、予測:タイプ別、用途別、地域別(2017年~2027年)
出版日: 2022年11月01日
発行: TechSci Research
ページ情報: 英文 114 Pages
納期: 2~3営業日
  • 全表示
  • 概要
  • 目次
概要

世界のマイクロバイオーム治療市場は、予測期間中の2023年~2027年に目覚ましい成長を遂げると予測されています。

背景として、フェニルケトン尿症、肝性脳症、C.ディフィシル感染症(CDI)などの疾患の有病率上昇による正確で迅速な治療の必要性が挙げられ、これが予測期間中の世界のマイクロバイオーム治療市場の成長を促進すると期待されます。

また、マイクロバイオームを用いた治療法の発見は新たな分野であり、世界中の学者、研究者、様々なバイオテクノロジー・製薬会社の注目により、マイクロバイオーム治療に関連する研究・臨床試験がここ数年で大幅に増加しています。これが、予測期間中の市場成長に有利な機会を生み出す見通しです。

当レポートでは、世界のマイクロバイオーム治療市場について調査分析し、セグメント別・地域別の市場規模・シェア予測、市場力学、企業プロファイルなど、体系的な情報を提供しています。

目次

第1章 製品概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 COVID-19が世界のマイクロバイオーム治療市場に与える影響

第5章 VOC(顧客の声)

第6章 臨床試験分析

第7章 世界のマイクロバイオーム治療市場の展望

  • 市場規模と予測
    • 金額別
  • 市場シェアと予測
    • タイプ別(FMTとマイクロバイオーム薬)
    • 用途別(C.ディフィシル感染症、クローン病、炎症性腸疾患、糖尿病、その他)
    • 地域別
    • 企業別(2021年)
  • 製品市場マップ

第8章 北米のマイクロバイオーム治療市場の展望

  • 市場規模と予測
    • 金額別
  • 市場シェアと予測
    • タイプ別
    • 用途別
    • 国別
  • 北米:国別分析
    • 米国
    • メキシコ
    • カナダ

第9章 欧州のマイクロバイオーム治療市場の展望

  • 市場規模と予測
    • 金額別
  • 市場シェアと予測
    • タイプ別
    • 用途別
    • 国別
  • 欧州:国別分析
    • フランス
    • ドイツ
    • 英国
    • イタリア
    • スペイン

第10章 アジア太平洋のマイクロバイオーム治療市場の展望

  • 市場規模と予測
    • 金額別
  • 市場シェアと予測
    • タイプ別
    • 用途別
    • 国別
  • アジア太平洋:国別分析
    • 中国
    • インド
    • 韓国
    • 日本
    • オーストラリア

第11章 南米のマイクロバイオーム治療市場の展望

  • 市場規模と予測
    • 金額別
  • 市場シェアと予測
    • タイプ別
    • 用途別
    • 国別
  • 南米:国別分析
    • ブラジル
    • アルゼンチン
    • コロンビア

第12章 中東・アフリカのマイクロバイオーム治療市場の展望

  • 市場規模と予測
    • 金額別
  • 市場シェアと予測
    • タイプ別
    • 用途別
    • 国別
  • MEA:国別分析
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦

第13章 市場力学

  • 促進要因
  • 課題

第14章 市場の動向と開発

第15章 競合情勢

  • 4D Pharma plc
  • Enterome SA
  • Finch Therapeutics Group, Inc.
  • Vedanta Bioscience, Inc.
  • Seres Therapeutics, Inc.
  • Microbiotica Limited
  • Destiny Pharma plc
  • Taisho Pharmaceutical Holdings Co., Ltd.
  • AOBiome Therapeutics, Inc.
  • Ferring Pharmaceuticals SA

第16章 戦略的提言

目次
Product Code: 12867

The global microbiome therapeutics market is anticipated to witness an impressive growth during the forecast period, 2023-2027. This can be ascribed to the growing prevalence of diseases like phenylketonuria, hepatic encephalopathy, C. difficile infection (CDI), among others and requirement for a precise and faster treatment. This in turn is expected to drive the growth of global microbiome therapeutics market during the forecast period. Additionally, finding therapeutic solutions using microbiome is an emerging field and is attracting the attention of academicians, researchers, and various biotechnology & pharmaceutical companies across the globe. The research, clinical trials related to microbiome therapeutics have significantly increased over the years. According to clinicaltrials.gov, there are around 188 clinical trials registered on its portal related to microbiome therapeutics. This in turn is expected to create lucrative opportunities for the market growth during the forecast period.

Increasing Focus on Human Microbiome Therapeutics Development

The increase prevalence of different types of diseases, failure of current treatment options in providing accurate cure, among others have led to a shift towards alternative therapeutics such as microbiome therapeutics. Being an emerging field, microbiome therapeutics is receiving the attention of research fraternity across the globe. As a result of this a lot of drug discovery and development is happening. As of now there is no approved product and major products are in early stages of clinical trials, in phases I and II. However, companies are advancing their research and may be in the near future an approved microbiome therapeutic product will be available in the market. For instance, in 2021, Seres Therapeutics, Inc. announced data of SER-109, released from its Phase 3 ECOSPOR III study. The pipeline drug is under investigation as an oral therapy for recurring C. difficile infection with an anticipated launch in the first half of 2023.

Growing Funding Activities, Collaborations

The growing collaborations, partnerships, mergers & acquisitions and other strategies followed by various biotechnology & pharmaceutical companies in order to develop a potential microbiome therapeutics is expected to support the market growth in the coming years. For instance, in March 2019, AstraZeneca Plc., collaborated with Seres Therapeutics, Inc. to determine the effect of microbiome environment in a patient undergoing immunotherapy for cancer. Similarly in 2016, AbbVie Inc. entered into a partnership with Synlogic, Inc. for the development of drug for inflammatory bowel disorders. Additionally, increasing funding by different government and non-government organizations across the globe to support research & development activities related to microbiome therapeutics is expected to create lucrative opportunities for the market growth in the next few years. For instance, in 2016, the United States federal government announced USD 121 million for Microbiome Initiative, to provide and coordinate funds for microbiome research.

Market Segmentation

The global microbiome therapeutics market can be segmented into by type, by application, by region, and by company. Based on by type, the market can be divided into FMT and microbiome drugs. Based on application, the market can be categorized into C. Difficile, crohn's disease, inflammatory bowel disease, diabetes, and others. Regionally, North America dominated the market followed Europe, Asia Pacific, South America and Middle East & Africa. In terms of country, the United States is dominating the overall global microbiome therapeutics market. This can be ascribed to the increasing funding activities in the United States. For instance, the total biotechnology companies funding in the United States stood around USD99.4 billion.

Market Players

4D Pharma plc, Enterome SA, Finch Therapeutics Group, Inc., Vedanta Bioscience, Inc., Seres Therapeutics, Inc., Microbiotica Limited, Destiny Pharma plc, Taisho Pharmaceutical Holdings Co., Ltd., AOBiome Therapeutics, Inc., Ferring Pharmaceuticals SA are some of the leading players operating in the global microbiome therapeutics market.

Report Scope:

In this report, global microbiome therapeutics market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

Microbiome Therapeutics Market, By Type:

  • FMT
  • Microbiome Drugs

Microbiome Therapeutics Market, By Application:

  • C. Difficile
  • Crohn's Disease
  • Inflammatory Bowel Disease
  • Diabetes
  • Others

Microbiome Therapeutics Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • United Kingdom
    • Spain
    • Italy
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global Microbiome Therapeutics market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Impact of COVID-19 on Global Microbiome Therapeutics Market

5. Voice of Customer

6. Clinical Trial Analysis

7. Global Microbiome Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type (FMT v/s Microbiome Drugs)
    • 7.2.2. By Application (C. Difficile, Crohn's Disease, Inflammatory Bowel Disease, Diabetes, Others)
    • 7.2.3. By Region
    • 7.2.4. By Company (2021)
  • 7.3. Product Market Map

8. North America Microbiome Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Application
    • 8.2.3. By Country
  • 8.3. North America: Country Analysis
    • 8.3.1. United States Microbiome Therapeutics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Application
    • 8.3.2. Mexico Microbiome Therapeutics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Application
    • 8.3.3. Canada Microbiome Therapeutics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Application

9. Europe Microbiome Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Application
    • 9.2.3. By Country
  • 9.3. Europe: Country Analysis
    • 9.3.1. France Microbiome Therapeutics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Application
    • 9.3.2. Germany Microbiome Therapeutics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Application
    • 9.3.3. United Kingdom Microbiome Therapeutics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Application
    • 9.3.4. Italy Microbiome Therapeutics Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Type
        • 9.3.4.2.2. By Application
    • 9.3.5. Spain Microbiome Therapeutics Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By Type
        • 9.3.5.2.2. By Application

10. Asia-Pacific Microbiome Therapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Application
    • 10.2.3. By Country
  • 10.3. Asia-Pacific: Country Analysis
    • 10.3.1. China Microbiome Therapeutics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Application
    • 10.3.2. India Microbiome Therapeutics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Application
    • 10.3.3. South Korea Microbiome Therapeutics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Application
    • 10.3.4. Japan Microbiome Therapeutics Market Outlook
      • 10.3.4.1. Market Size & Forecast
        • 10.3.4.1.1. By Value
      • 10.3.4.2. Market Share & Forecast
        • 10.3.4.2.1. By Type
        • 10.3.4.2.2. By Application
    • 10.3.5. Australia Microbiome Therapeutics Market Outlook
      • 10.3.5.1. Market Size & Forecast
        • 10.3.5.1.1. By Value
      • 10.3.5.2. Market Share & Forecast
        • 10.3.5.2.1. By Type
        • 10.3.5.2.2. By Application

11. South America Microbiome Therapeutics Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Type
    • 11.2.2. By Application
    • 11.2.3. By Country
  • 11.3. South America: Country Analysis
    • 11.3.1. Brazil Microbiome Therapeutics Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Type
        • 11.3.1.2.2. By Application
    • 11.3.2. Argentina Microbiome Therapeutics Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Type
        • 11.3.2.2.2. By Application
    • 11.3.3. Colombia Microbiome Therapeutics Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Type
        • 11.3.3.2.2. By Application

12. Middle East and Africa Microbiome Therapeutics Market Outlook

  • 12.1. Market Size & Forecast
    • 12.1.1. By Value
  • 12.2. Market Share & Forecast
    • 12.2.1. By Type
    • 12.2.2. By Application
    • 12.2.3. By Country
  • 12.3. MEA: Country Analysis
    • 12.3.1. South Africa Microbiome Therapeutics Market Outlook
      • 12.3.1.1. Market Size & Forecast
        • 12.3.1.1.1. By Value
      • 12.3.1.2. Market Share & Forecast
        • 12.3.1.2.1. By Type
        • 12.3.1.2.2. By Application
    • 12.3.2. Saudi Arabia Microbiome Therapeutics Market Outlook
      • 12.3.2.1. Market Size & Forecast
        • 12.3.2.1.1. By Value
      • 12.3.2.2. Market Share & Forecast
        • 12.3.2.2.1. By Type
        • 12.3.2.2.2. By Application
    • 12.3.3. UAE Microbiome Therapeutics Market Outlook
      • 12.3.3.1. Market Size & Forecast
        • 12.3.3.1.1. By Value
      • 12.3.3.2. Market Share & Forecast
        • 12.3.3.2.1. By Type
        • 12.3.3.2.2. By Application

13. Market Dynamics

  • 13.1. Drivers
  • 13.2. Challenges

14. Market Trends & Developments

15. Competitive Landscape

  • 15.1. 4D Pharma plc
  • 15.2. Enterome SA
  • 15.3. Finch Therapeutics Group, Inc.
  • 15.4. Vedanta Bioscience, Inc.
  • 15.5. Seres Therapeutics, Inc.
  • 15.6. Microbiotica Limited
  • 15.7. Destiny Pharma plc
  • 15.8. Taisho Pharmaceutical Holdings Co., Ltd.
  • 15.9. AOBiome Therapeutics, Inc.
  • 15.10. Ferring Pharmaceuticals SA

16. Strategic Recommendations